BioNexus Gene Lab Corp. (BGLC) 10-Year Financial Performance & Capital Metrics

BGLC • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesSpecialized Testing Laboratories

AboutBioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.Show more

Revenue $10M -2.7%
EBITDA -$1M +42.8%
Net Income -$2M +39.2%
EPS (Diluted) -0.90 +41.2%
Gross Margin 13.56% -0.4%
EBITDA Margin -14.94% +41.3%
Operating Margin -16.55% +37.7%
Net Margin -16.81% +37.5%
ROE -17.78% +44.8%
ROIC -29.39% +35.9%
Debt/Equity 0.03 +66.7%
Interest Coverage -74.42 +60.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 137.1%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y137.09%

3Y-10.72%

TTM2.22%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-143.67%

EPS CAGR

10Y-

5Y-

3Y-

TTM-140.21%

ROCE

10Y Avg-34.97%

5Y Avg-1.12%

3Y Avg-17.61%

Latest-17.24%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	107.68K	212.33K	126.95K	11.39M	13.36M	10.93M	9.77M	9.51M
Revenue Growth %	-	-	0.97%	-0.4%	88.72%	0.17%	-0.18%	-0.11%	-0.03%
Cost of Goods Sold+	0	28.87K	183.56K	71.07K	9.67M	11.17M	9.67M	8.44M	8.22M
COGS % of Revenue	-	0.27%	0.86%	0.56%	0.85%	0.84%	0.88%	0.86%	0.86%
Gross Profit+	0	78.81K	28.77K	55.89K	1.72M	2.19M	1.26M	1.33M	1.29M
Gross Margin %	-	0.73%	0.14%	0.44%	0.15%	0.16%	0.12%	0.14%	0.14%
Gross Profit Growth %	-	-	-0.64%	0.94%	29.77%	0.28%	-0.43%	0.06%	-0.03%
Operating Expenses+	835	206.72K	-31.14K	331.59K	446K	1.14M	1.55M	3.92M	2.86M
OpEx % of Revenue	-	1.92%	-0.15%	2.61%	0.04%	0.09%	0.14%	0.4%	0.3%
Selling, General & Admin	835	206.72K	241.93K	356.64K	1.33M	1.2M	1.73M	3.04M	4M
SG&A % of Revenue	-	1.92%	1.14%	2.81%	0.12%	0.09%	0.16%	0.31%	0.42%
Research & Development	0	0	0	0	0	0	0	54.98K	47.51K
R&D % of Revenue	-	-	-	-	-	-	-	0.01%	0%
Other Operating Expenses	0	0	-273.07K	-25.05K	-886.94K	-66.49K	-179.28K	828.39K	-1.19M
Operating Income+	-840	-127.91K	59.9K	-275.7K	1.27M	1.06M	-291.18K	-2.59M	-1.57M
Operating Margin %	-	-1.19%	0.28%	-2.17%	0.11%	0.08%	-0.03%	-0.27%	-0.17%
Operating Income Growth %	-	-151.27%	1.47%	-5.6%	5.62%	-0.17%	-1.28%	-7.91%	0.39%
EBITDA+	-5	-112.88K	100.51K	-222.37K	1.38M	1.16M	-185.76K	-2.49M	-1.42M
EBITDA Margin %	-	-1.05%	0.47%	-1.75%	0.12%	0.09%	-0.02%	-0.25%	-0.15%
EBITDA Growth %	-	-22574.8%	1.89%	-3.21%	7.19%	-0.15%	-1.16%	-12.38%	0.43%
D&A (Non-Cash Add-back)	835	15.03K	40.61K	53.33K	101.6K	108.22K	105.42K	108.42K	153.14K
EBIT	-835	-119.42K	59.9K	-275.7K	1.27M	1.06M	-291.18K	-2.59M	-1.57M
Net Interest Income+	0	0	0	0	-11.31K	-12.97K	-12.48K	-13.93K	126.5K
Interest Income	0	0	0	0	0	0	0	0	147.64K
Interest Expense	0	0	0	0	11.31K	12.97K	12.48K	13.93K	21.15K
Other Income/Expense	5	0	0	0	-11.31K	-12.97K	-12.48K	-13.93K	-21.15K
Pretax Income+	-835	-119.41K	59.9K	-275.7K	1.26M	1.04M	-303.66K	-2.61M	-1.59M
Pretax Margin %	-	-1.11%	0.28%	-2.17%	0.11%	0.08%	-0.03%	-0.27%	-0.17%
Income Tax+	0	4.34K	33.45K	-29.24K	168.41K	291.28K	52.31K	21.53K	3.49K
Effective Tax Rate %	1%	1.04%	0.44%	0.89%	0.87%	0.72%	1.17%	1.01%	1%
Net Income+	-835	-123.75K	26.45K	-246.47K	1.09M	751.57K	-355.97K	-2.63M	-1.6M
Net Margin %	-	-1.15%	0.12%	-1.94%	0.1%	0.06%	-0.03%	-0.27%	-0.17%
Net Income Growth %	-	-147.2%	1.21%	-10.32%	5.44%	-0.31%	-1.47%	-6.39%	0.39%
Net Income (Continuing)	-835	-123.75K	26.45K	-246.47K	1.09M	751.57K	-355.97K	-2.63M	-1.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.00	-0.02	0.00	-0.03	1.28	0.53	-0.25	-1.53	-0.90
EPS Growth %	-	-	1.24%	-	38.43%	-0.59%	-1.47%	-5.12%	0.41%
EPS (Basic)	-0.00	-0.02	0.00	-0.03	1.28	0.53	-0.25	-1.53	-0.90
Diluted Shares Outstanding	621.9K	621.9K	552.8K	719.74K	857.65K	1.43M	1.44M	1.72M	1.78M
Basic Shares Outstanding	621.9K	621.9K	552.8K	719.74K	857.65K	1.43M	1.44M	1.72M	1.78M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26	999.72K	1.3M	882.57K	7.99M	7.08M	6.02M	8.05M	7.43M
Cash & Short-Term Investments	26	839.14K	1.26M	859.08K	2.79M	2.12M	2.12M	5.93M	4.38M
Cash Only	26	839.14K	659.24K	859.08K	2.79M	2.12M	2.12M	5.93M	4.38M
Short-Term Investments	0	0	601K	0	0	0	0	0	0
Accounts Receivable	0	0	0	2.86K	4M	3.36M	2.9M	857.26K	1.58M
Days Sales Outstanding	-	-	-	8.22	128.15	91.69	96.85	32.02	60.65
Inventory	0	32.09K	15.3K	7.58K	1.18M	1.52M	977.81K	1.14M	1.39M
Days Inventory Outstanding	-	405.65	30.42	38.93	44.39	49.74	36.91	49.2	61.65
Other Current Assets	0	125.94K	22.81K	13.06K	22.64K	79.52K	25.24K	122.43K	84.17K
Total Non-Current Assets+	0	273.16K	353.88K	348.67K	2.13M	2.49M	2.72M	3.35M	3M
Property, Plant & Equipment	0	273.16K	341.81K	336.45K	1.85M	1.68M	1.57M	1.65M	1.74M
Fixed Asset Turnover	-	0.39x	0.62x	0.38x	6.16x	7.98x	6.97x	5.91x	5.47x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	12.08K	12.21K	281.67K	749.03K	1.15M	1.7M	1.27M
Other Non-Current Assets	0	0	0	0	0	67.61K	0	0	0
Total Assets+	26	1.27M	1.65M	1.23M	10.12M	9.57M	8.74M	11.4M	10.43M
Asset Turnover	-	0.08x	0.13x	0.10x	1.13x	1.40x	1.25x	0.86x	0.91x
Asset Growth %	-	48955.92%	0.3%	-0.25%	7.22%	-0.05%	-0.09%	0.3%	-0.08%
Total Current Liabilities+	1.34K	1.17M	62.89K	51.57K	3.37M	2.33M	2M	1.63M	1.95M
Accounts Payable	1.34K	35.09K	0	0	3.17M	2.01M	1.86M	1.4M	1.5M
Days Payables Outstanding	-	443.65	-	-	119.67	65.76	70.25	60.63	66.74
Short-Term Debt	0	0	0	32.14K	45.75K	39.51K	16.57K	13.2K	0
Deferred Revenue (Current)	0	0	0	0	0	107.58K	23.12K	0	95.88K
Other Current Liabilities	-1.34K	1.04M	11.15K	19.44K	95.88K	71.81K	103.37K	180.91K	301.28K
Current Ratio	0.02x	0.85x	20.64x	17.11x	2.37x	3.04x	3.00x	4.93x	3.81x
Quick Ratio	0.02x	0.82x	20.40x	16.97x	2.02x	2.39x	2.52x	4.24x	3.10x
Cash Conversion Cycle	-	-	-	-	52.87	75.67	63.51	20.59	55.55
Total Non-Current Liabilities+	0	4.57K	67.42K	57.3K	79.54K	65.86K	71.07K	111.02K	159.74K
Long-Term Debt	0	0	0	45.09K	0	0	0	0	0
Capital Lease Obligations	0	0	62.94K	12.21K	77.67K	37.44K	40.21K	98.76K	159.74K
Deferred Tax Liabilities	0	4.57K	0	0	1.87K	28.42K	30.87K	12.26K	0
Other Non-Current Liabilities	0	0	4.49K	0	0	0	0	12.26K	0
Total Liabilities	1.34K	1.18M	130.31K	108.87K	3.45M	2.39M	2.08M	1.74M	2.11M
Total Debt+	0	0	82.06K	89.44K	123.42K	76.95K	56.77K	146.59K	210.56K
Net Debt	-26	-839.14K	-577.17K	-769.64K	-2.66M	-2.05M	-2.06M	-5.78M	-4.17M
Debt / Equity	-	-	0.05x	0.08x	0.02x	0.01x	0.01x	0.02x	0.03x
Debt / EBITDA	-	-	0.82x	-	0.09x	0.07x	-	-	-
Net Debt / EBITDA	-	-	-5.74x	-	-1.94x	-1.76x	-	-	-
Interest Coverage	-	-	-	-	112.60x	81.39x	-23.33x	-186.20x	-74.42x
Total Equity+	-1.31K	94.63K	1.52M	1.12M	6.66M	7.18M	6.67M	9.66M	8.32M
Equity Growth %	-	73.18%	15.08%	-0.26%	4.94%	0.08%	-0.07%	0.45%	-0.14%
Book Value per Share	-0.00	0.15	2.75	1.56	7.77	5.03	4.63	5.61	4.67
Total Shareholders' Equity	-1.31K	94.63K	1.52M	1.12M	6.66M	7.18M	6.67M	9.66M	8.32M
Common Stock	0	5.21M	6.65M	6.48M	10.78M	10.78M	10.93M	17.19M	17.33M
Retained Earnings	-1.44K	-113.3K	-86.84K	-333.31K	760.79K	1.51M	1.16M	-1.84M	-3.44M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	126	14.05K	-5.04M	-17.1K	133.68K	-100.26K	-409.06K	-677.29K	-555K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-835	357.22K	-274.08K	-217.27K	552.68K	9.16K	551.82K	-1.76M	-2.23M
Operating CF Margin %	-	3.32%	-1.29%	-1.71%	0.05%	0%	0.05%	-0.18%	-0.23%
Operating CF Growth %	-	428.8%	-1.77%	0.21%	3.54%	-0.98%	59.24%	-4.19%	-0.27%
Net Income	-835	-123.75K	26.45K	-246.47K	1.09M	751.57K	-355.97K	-2.63M	-1.6M
Depreciation & Amortization	0	15.03K	40.61K	53.33K	101.6K	108.22K	105.42K	108.42K	153.14K
Stock-Based Compensation	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	0	-382.62K	0	0	-745.38K	11.62K	-31.02K	641.84K	-904.46K
Working Capital Changes	0	439.31K	-341.14K	-24.14K	102.36K	-862.25K	833.38K	117.98K	115.4K
Change in Receivables	0	-6.49K	105.67K	9.76K	411.07K	579.22K	538.65K	606.16K	147.76K
Change in Inventory	0	-32.09K	16.79K	7.72K	147.04K	-345.75K	544.11K	-160.39K	-250.85K
Change in Payables	0	477.88K	0	0	-524.24K	0	0	-381.29K	0
Cash from Investing+	0	-5.31M	-51.7K	-12.82K	1.32M	-490.57K	-450.5K	-1.86M	418.2K
Capital Expenditures	0	-314.82K	-39.62K	-12.82K	-421.62K	-3.16K	-54.17K	-149.4K	-226.99K
CapEx % of Revenue	-	2.92%	0.19%	0.1%	0.04%	0%	0%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	1.47M	22.04K	115.38K	-1.41M	147.98K
Cash from Financing+	638	5.78M	742.94K	-180.81K	-4.95K	-28.22K	108.17K	6.27M	144.97K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	638	5.78M	742.94K	-164.03K	0	-1.92K	-7.79K	524.94K	144.97K
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-835	42.4K	-313.7K	-230.09K	131.06K	6K	497.65K	-1.91M	-2.46M
FCF Margin %	-	0.39%	-1.48%	-1.81%	0.01%	0%	0.05%	-0.2%	-0.26%
FCF Growth %	-	51.77%	-8.4%	0.27%	1.57%	-0.95%	81.96%	-4.84%	-0.29%
FCF per Share	-0.00	0.07	-0.57	-0.32	0.15	0.00	0.35	-1.11	-1.38
FCF Conversion (FCF/Net Income)	1.00x	-2.89x	-10.36x	0.88x	0.51x	0.01x	-1.55x	0.67x	1.40x
Interest Paid	0	0	4.32K	5.05K	11.31K	12.97K	12.48K	0	9.35K
Taxes Paid	0	0	0	10.71K	143.5K	226.77K	170.45K	0	40.38K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-265.23%	3.27%	-18.64%	28.11%	10.86%	-5.14%	-32.21%	-17.78%
Return on Invested Capital (ROIC)	-	-	44.87%	-31.87%	43.92%	17.35%	-4.49%	-45.89%	-29.39%
Gross Margin	-	73.19%	13.55%	44.02%	15.1%	16.42%	11.52%	13.61%	13.56%
Net Margin	-	-114.92%	12.46%	-194.14%	9.61%	5.62%	-3.26%	-26.91%	-16.81%
Debt / Equity	-	-	0.05x	0.08x	0.02x	0.01x	0.01x	0.02x	0.03x
Interest Coverage	-	-	-	-	112.60x	81.39x	-23.33x	-186.20x	-74.42x
FCF Conversion	1.00x	-2.89x	-10.36x	0.88x	0.51x	0.01x	-1.55x	0.67x	1.40x
Revenue Growth	-	-	97.18%	-40.21%	8872.03%	17.31%	-18.21%	-10.6%	-2.66%

Revenue by Geography

	2024
Singapore	572.03K
Singapore Growth	-
Sri Lanka	459K
Sri Lanka Growth	-
Indonesia	138.3K
Indonesia Growth	-

Frequently Asked Questions

Growth & Financials

BioNexus Gene Lab Corp. (BGLC) reported $9.5M in revenue for fiscal year 2024.

BioNexus Gene Lab Corp. (BGLC) saw revenue decline by 2.7% over the past year.

BioNexus Gene Lab Corp. (BGLC) reported a net loss of $2.3M for fiscal year 2024.

Dividend & Returns

BioNexus Gene Lab Corp. (BGLC) has a return on equity (ROE) of -17.8%. Negative ROE indicates the company is unprofitable.

BioNexus Gene Lab Corp. (BGLC) had negative free cash flow of $2.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

BioNexus Gene Lab Corp. (BGLC) 10-Year Financial Performance & Capital Metrics

BGLC • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesSpecialized Testing Laboratories

Revenue $10M -2.7%
EBITDA -$1M +42.8%
Net Income -$2M +39.2%
EPS (Diluted) -0.90 +41.2%
Gross Margin 13.56% -0.4%
EBITDA Margin -14.94% +41.3%
Operating Margin -16.55% +37.7%
Net Margin -16.81% +37.5%
ROE -17.78% +44.8%
ROIC -29.39% +35.9%
Debt/Equity 0.03 +66.7%
Interest Coverage -74.42 +60.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 137.1%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y137.09%

3Y-10.72%

TTM2.22%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-143.67%

EPS CAGR

10Y-

5Y-

3Y-

TTM-140.21%

ROCE

10Y Avg-34.97%

5Y Avg-1.12%

3Y Avg-17.61%

Latest-17.24%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	107.68K	212.33K	126.95K	11.39M	13.36M	10.93M	9.77M	9.51M
Revenue Growth %	-	-	0.97%	-0.4%	88.72%	0.17%	-0.18%	-0.11%	-0.03%
Cost of Goods Sold+	0	28.87K	183.56K	71.07K	9.67M	11.17M	9.67M	8.44M	8.22M
COGS % of Revenue	-	0.27%	0.86%	0.56%	0.85%	0.84%	0.88%	0.86%	0.86%
Gross Profit+	0	78.81K	28.77K	55.89K	1.72M	2.19M	1.26M	1.33M	1.29M
Gross Margin %	-	0.73%	0.14%	0.44%	0.15%	0.16%	0.12%	0.14%	0.14%
Gross Profit Growth %	-	-	-0.64%	0.94%	29.77%	0.28%	-0.43%	0.06%	-0.03%
Operating Expenses+	835	206.72K	-31.14K	331.59K	446K	1.14M	1.55M	3.92M	2.86M
OpEx % of Revenue	-	1.92%	-0.15%	2.61%	0.04%	0.09%	0.14%	0.4%	0.3%
Selling, General & Admin	835	206.72K	241.93K	356.64K	1.33M	1.2M	1.73M	3.04M	4M
SG&A % of Revenue	-	1.92%	1.14%	2.81%	0.12%	0.09%	0.16%	0.31%	0.42%
Research & Development	0	0	0	0	0	0	0	54.98K	47.51K
R&D % of Revenue	-	-	-	-	-	-	-	0.01%	0%
Other Operating Expenses	0	0	-273.07K	-25.05K	-886.94K	-66.49K	-179.28K	828.39K	-1.19M
Operating Income+	-840	-127.91K	59.9K	-275.7K	1.27M	1.06M	-291.18K	-2.59M	-1.57M
Operating Margin %	-	-1.19%	0.28%	-2.17%	0.11%	0.08%	-0.03%	-0.27%	-0.17%
Operating Income Growth %	-	-151.27%	1.47%	-5.6%	5.62%	-0.17%	-1.28%	-7.91%	0.39%
EBITDA+	-5	-112.88K	100.51K	-222.37K	1.38M	1.16M	-185.76K	-2.49M	-1.42M
EBITDA Margin %	-	-1.05%	0.47%	-1.75%	0.12%	0.09%	-0.02%	-0.25%	-0.15%
EBITDA Growth %	-	-22574.8%	1.89%	-3.21%	7.19%	-0.15%	-1.16%	-12.38%	0.43%
D&A (Non-Cash Add-back)	835	15.03K	40.61K	53.33K	101.6K	108.22K	105.42K	108.42K	153.14K
EBIT	-835	-119.42K	59.9K	-275.7K	1.27M	1.06M	-291.18K	-2.59M	-1.57M
Net Interest Income+	0	0	0	0	-11.31K	-12.97K	-12.48K	-13.93K	126.5K
Interest Income	0	0	0	0	0	0	0	0	147.64K
Interest Expense	0	0	0	0	11.31K	12.97K	12.48K	13.93K	21.15K
Other Income/Expense	5	0	0	0	-11.31K	-12.97K	-12.48K	-13.93K	-21.15K
Pretax Income+	-835	-119.41K	59.9K	-275.7K	1.26M	1.04M	-303.66K	-2.61M	-1.59M
Pretax Margin %	-	-1.11%	0.28%	-2.17%	0.11%	0.08%	-0.03%	-0.27%	-0.17%
Income Tax+	0	4.34K	33.45K	-29.24K	168.41K	291.28K	52.31K	21.53K	3.49K
Effective Tax Rate %	1%	1.04%	0.44%	0.89%	0.87%	0.72%	1.17%	1.01%	1%
Net Income+	-835	-123.75K	26.45K	-246.47K	1.09M	751.57K	-355.97K	-2.63M	-1.6M
Net Margin %	-	-1.15%	0.12%	-1.94%	0.1%	0.06%	-0.03%	-0.27%	-0.17%
Net Income Growth %	-	-147.2%	1.21%	-10.32%	5.44%	-0.31%	-1.47%	-6.39%	0.39%
Net Income (Continuing)	-835	-123.75K	26.45K	-246.47K	1.09M	751.57K	-355.97K	-2.63M	-1.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.00	-0.02	0.00	-0.03	1.28	0.53	-0.25	-1.53	-0.90
EPS Growth %	-	-	1.24%	-	38.43%	-0.59%	-1.47%	-5.12%	0.41%
EPS (Basic)	-0.00	-0.02	0.00	-0.03	1.28	0.53	-0.25	-1.53	-0.90
Diluted Shares Outstanding	621.9K	621.9K	552.8K	719.74K	857.65K	1.43M	1.44M	1.72M	1.78M
Basic Shares Outstanding	621.9K	621.9K	552.8K	719.74K	857.65K	1.43M	1.44M	1.72M	1.78M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26	999.72K	1.3M	882.57K	7.99M	7.08M	6.02M	8.05M	7.43M
Cash & Short-Term Investments	26	839.14K	1.26M	859.08K	2.79M	2.12M	2.12M	5.93M	4.38M
Cash Only	26	839.14K	659.24K	859.08K	2.79M	2.12M	2.12M	5.93M	4.38M
Short-Term Investments	0	0	601K	0	0	0	0	0	0
Accounts Receivable	0	0	0	2.86K	4M	3.36M	2.9M	857.26K	1.58M
Days Sales Outstanding	-	-	-	8.22	128.15	91.69	96.85	32.02	60.65
Inventory	0	32.09K	15.3K	7.58K	1.18M	1.52M	977.81K	1.14M	1.39M
Days Inventory Outstanding	-	405.65	30.42	38.93	44.39	49.74	36.91	49.2	61.65
Other Current Assets	0	125.94K	22.81K	13.06K	22.64K	79.52K	25.24K	122.43K	84.17K
Total Non-Current Assets+	0	273.16K	353.88K	348.67K	2.13M	2.49M	2.72M	3.35M	3M
Property, Plant & Equipment	0	273.16K	341.81K	336.45K	1.85M	1.68M	1.57M	1.65M	1.74M
Fixed Asset Turnover	-	0.39x	0.62x	0.38x	6.16x	7.98x	6.97x	5.91x	5.47x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	12.08K	12.21K	281.67K	749.03K	1.15M	1.7M	1.27M
Other Non-Current Assets	0	0	0	0	0	67.61K	0	0	0
Total Assets+	26	1.27M	1.65M	1.23M	10.12M	9.57M	8.74M	11.4M	10.43M
Asset Turnover	-	0.08x	0.13x	0.10x	1.13x	1.40x	1.25x	0.86x	0.91x
Asset Growth %	-	48955.92%	0.3%	-0.25%	7.22%	-0.05%	-0.09%	0.3%	-0.08%
Total Current Liabilities+	1.34K	1.17M	62.89K	51.57K	3.37M	2.33M	2M	1.63M	1.95M
Accounts Payable	1.34K	35.09K	0	0	3.17M	2.01M	1.86M	1.4M	1.5M
Days Payables Outstanding	-	443.65	-	-	119.67	65.76	70.25	60.63	66.74
Short-Term Debt	0	0	0	32.14K	45.75K	39.51K	16.57K	13.2K	0
Deferred Revenue (Current)	0	0	0	0	0	107.58K	23.12K	0	95.88K
Other Current Liabilities	-1.34K	1.04M	11.15K	19.44K	95.88K	71.81K	103.37K	180.91K	301.28K
Current Ratio	0.02x	0.85x	20.64x	17.11x	2.37x	3.04x	3.00x	4.93x	3.81x
Quick Ratio	0.02x	0.82x	20.40x	16.97x	2.02x	2.39x	2.52x	4.24x	3.10x
Cash Conversion Cycle	-	-	-	-	52.87	75.67	63.51	20.59	55.55
Total Non-Current Liabilities+	0	4.57K	67.42K	57.3K	79.54K	65.86K	71.07K	111.02K	159.74K
Long-Term Debt	0	0	0	45.09K	0	0	0	0	0
Capital Lease Obligations	0	0	62.94K	12.21K	77.67K	37.44K	40.21K	98.76K	159.74K
Deferred Tax Liabilities	0	4.57K	0	0	1.87K	28.42K	30.87K	12.26K	0
Other Non-Current Liabilities	0	0	4.49K	0	0	0	0	12.26K	0
Total Liabilities	1.34K	1.18M	130.31K	108.87K	3.45M	2.39M	2.08M	1.74M	2.11M
Total Debt+	0	0	82.06K	89.44K	123.42K	76.95K	56.77K	146.59K	210.56K
Net Debt	-26	-839.14K	-577.17K	-769.64K	-2.66M	-2.05M	-2.06M	-5.78M	-4.17M
Debt / Equity	-	-	0.05x	0.08x	0.02x	0.01x	0.01x	0.02x	0.03x
Debt / EBITDA	-	-	0.82x	-	0.09x	0.07x	-	-	-
Net Debt / EBITDA	-	-	-5.74x	-	-1.94x	-1.76x	-	-	-
Interest Coverage	-	-	-	-	112.60x	81.39x	-23.33x	-186.20x	-74.42x
Total Equity+	-1.31K	94.63K	1.52M	1.12M	6.66M	7.18M	6.67M	9.66M	8.32M
Equity Growth %	-	73.18%	15.08%	-0.26%	4.94%	0.08%	-0.07%	0.45%	-0.14%
Book Value per Share	-0.00	0.15	2.75	1.56	7.77	5.03	4.63	5.61	4.67
Total Shareholders' Equity	-1.31K	94.63K	1.52M	1.12M	6.66M	7.18M	6.67M	9.66M	8.32M
Common Stock	0	5.21M	6.65M	6.48M	10.78M	10.78M	10.93M	17.19M	17.33M
Retained Earnings	-1.44K	-113.3K	-86.84K	-333.31K	760.79K	1.51M	1.16M	-1.84M	-3.44M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	126	14.05K	-5.04M	-17.1K	133.68K	-100.26K	-409.06K	-677.29K	-555K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-835	357.22K	-274.08K	-217.27K	552.68K	9.16K	551.82K	-1.76M	-2.23M
Operating CF Margin %	-	3.32%	-1.29%	-1.71%	0.05%	0%	0.05%	-0.18%	-0.23%
Operating CF Growth %	-	428.8%	-1.77%	0.21%	3.54%	-0.98%	59.24%	-4.19%	-0.27%
Net Income	-835	-123.75K	26.45K	-246.47K	1.09M	751.57K	-355.97K	-2.63M	-1.6M
Depreciation & Amortization	0	15.03K	40.61K	53.33K	101.6K	108.22K	105.42K	108.42K	153.14K
Stock-Based Compensation	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	0	-382.62K	0	0	-745.38K	11.62K	-31.02K	641.84K	-904.46K
Working Capital Changes	0	439.31K	-341.14K	-24.14K	102.36K	-862.25K	833.38K	117.98K	115.4K
Change in Receivables	0	-6.49K	105.67K	9.76K	411.07K	579.22K	538.65K	606.16K	147.76K
Change in Inventory	0	-32.09K	16.79K	7.72K	147.04K	-345.75K	544.11K	-160.39K	-250.85K
Change in Payables	0	477.88K	0	0	-524.24K	0	0	-381.29K	0
Cash from Investing+	0	-5.31M	-51.7K	-12.82K	1.32M	-490.57K	-450.5K	-1.86M	418.2K
Capital Expenditures	0	-314.82K	-39.62K	-12.82K	-421.62K	-3.16K	-54.17K	-149.4K	-226.99K
CapEx % of Revenue	-	2.92%	0.19%	0.1%	0.04%	0%	0%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	1.47M	22.04K	115.38K	-1.41M	147.98K
Cash from Financing+	638	5.78M	742.94K	-180.81K	-4.95K	-28.22K	108.17K	6.27M	144.97K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	638	5.78M	742.94K	-164.03K	0	-1.92K	-7.79K	524.94K	144.97K
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-835	42.4K	-313.7K	-230.09K	131.06K	6K	497.65K	-1.91M	-2.46M
FCF Margin %	-	0.39%	-1.48%	-1.81%	0.01%	0%	0.05%	-0.2%	-0.26%
FCF Growth %	-	51.77%	-8.4%	0.27%	1.57%	-0.95%	81.96%	-4.84%	-0.29%
FCF per Share	-0.00	0.07	-0.57	-0.32	0.15	0.00	0.35	-1.11	-1.38
FCF Conversion (FCF/Net Income)	1.00x	-2.89x	-10.36x	0.88x	0.51x	0.01x	-1.55x	0.67x	1.40x
Interest Paid	0	0	4.32K	5.05K	11.31K	12.97K	12.48K	0	9.35K
Taxes Paid	0	0	0	10.71K	143.5K	226.77K	170.45K	0	40.38K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-265.23%	3.27%	-18.64%	28.11%	10.86%	-5.14%	-32.21%	-17.78%
Return on Invested Capital (ROIC)	-	-	44.87%	-31.87%	43.92%	17.35%	-4.49%	-45.89%	-29.39%
Gross Margin	-	73.19%	13.55%	44.02%	15.1%	16.42%	11.52%	13.61%	13.56%
Net Margin	-	-114.92%	12.46%	-194.14%	9.61%	5.62%	-3.26%	-26.91%	-16.81%
Debt / Equity	-	-	0.05x	0.08x	0.02x	0.01x	0.01x	0.02x	0.03x
Interest Coverage	-	-	-	-	112.60x	81.39x	-23.33x	-186.20x	-74.42x
FCF Conversion	1.00x	-2.89x	-10.36x	0.88x	0.51x	0.01x	-1.55x	0.67x	1.40x
Revenue Growth	-	-	97.18%	-40.21%	8872.03%	17.31%	-18.21%	-10.6%	-2.66%

Revenue by Geography

	2024
Singapore	572.03K
Singapore Growth	-
Sri Lanka	459K
Sri Lanka Growth	-
Indonesia	138.3K
Indonesia Growth	-

Frequently Asked Questions

Growth & Financials

BioNexus Gene Lab Corp. (BGLC) reported $9.5M in revenue for fiscal year 2024.

BioNexus Gene Lab Corp. (BGLC) saw revenue decline by 2.7% over the past year.

BioNexus Gene Lab Corp. (BGLC) reported a net loss of $2.3M for fiscal year 2024.

Dividend & Returns

BioNexus Gene Lab Corp. (BGLC) has a return on equity (ROE) of -17.8%. Negative ROE indicates the company is unprofitable.

BioNexus Gene Lab Corp. (BGLC) had negative free cash flow of $2.9M in fiscal year 2024, likely due to heavy capital investments.